PT-141 (Bremelanotide) is a synthetic cyclic peptide belonging to the melanocortin family. It was developed through research into melanocortin receptor signalling and its influence on sexual motivation, neurological pathways and physiological responses.
Unlike conventional erectile dysfunction medications such as Sildenafil or Tadalafil, which primarily influence peripheral vascular mechanisms, PT-141 acts through the central nervous system.
Its primary pharmacological interest lies in its interaction with melanocortin receptors, particularly the MC3R and MC4R receptor subtypes.
Bremelanotide has been investigated for hypoactive sexual desire disorder (HSDD), and a prescription formulation has received regulatory approval in the United States for a specific indication in premenopausal women.
Chemical Identity & Structure
- Compound name: Bremelanotide
- Common designation: PT-141
- Chemical class: Synthetic melanocortin peptide
- Peptide type: Cyclic heptapeptide analogue
- Molecular formula: C₅₀H₆₈N₁₄O₁₀
- Molecular weight: Approximately 1025.2 g/mol
- Parent research compound: Melanotan II
- Primary receptor targets: MC3R and MC4R
PT-141 is structurally related to Melanotan II but has a modified peptide structure designed to retain melanocortin activity while reducing certain unwanted effects associated with its parent compound.
Mechanism of Action
PT-141 differs from conventional sexual-performance medications because its primary mechanism involves central melanocortin signalling rather than direct vascular stimulation.
Its pharmacological activity is associated with the following pathways:
1. Melanocortin Receptor Activation
PT-141 activates melanocortin receptors, particularly MC4R, which are involved in several neurological processes.
These receptors participate in:
- Sexual motivation and behavioural signalling.
- Central nervous system regulation.
- Appetite and energy balance.
- Neuroendocrine signalling.
2. Central Sexual Response Pathways
Melanocortin signalling is involved in neurological pathways associated with sexual desire and arousal.
Research suggests that activation of these pathways can influence sexual motivation independently of the peripheral vascular mechanisms targeted by PDE5 inhibitors.
3. Differences from PDE5 Inhibitors
Unlike Sildenafil and Tadalafil, PT-141 does not primarily work by inhibiting phosphodiesterase type 5.
This distinction makes it particularly interesting in research investigating central versus peripheral mechanisms of sexual function.
Pharmacological Research Profile
Bremelanotide is a non-selective melanocortin receptor agonist. According to its prescribing information, its receptor activity follows this approximate order:
- MC1R
- MC4R
- MC3R
- MC5R
- MC2R
At therapeutic exposure, MC1R and MC4R interactions are particularly relevant.
An important distinction is that although melanocortin receptor activation is established, the precise mechanism through which Bremelanotide improves sexual desire has not been fully determined.
Pharmacokinetics
Clinical studies of the approved injectable formulation have established several pharmacokinetic characteristics:
- Absorption: Rapid absorption following subcutaneous administration.
- Time to peak concentration: Approximately 1 hour.
- Elimination half-life: Approximately 2.7 hours.
- Metabolism: Peptide degradation into smaller peptide fragments and amino acids.
- Elimination: Primarily through metabolic degradation and subsequent excretion.
These characteristics describe the approved pharmaceutical formulation and should not automatically be extrapolated to unverified research-grade preparations.
Research Applications
PT-141 is relevant to several areas of biomedical investigation:
- Melanocortin receptor pharmacology.
- Central nervous system signalling.
- Sexual motivation and behavioural neuroscience.
- Neuroendocrine regulation.
- Hypoactive sexual desire disorder research.
- Peptide structure–activity relationship studies.
- Comparison of central and peripheral sexual-function mechanisms.
PT-141 Compared with Traditional ED Medications
| Characteristic | PT-141 | Sildenafil | Tadalafil |
|---|---|---|---|
| Active compound | Bremelanotide | Sildenafil | Tadalafil |
| Drug class | Melanocortin agonist | PDE5 inhibitor | PDE5 inhibitor |
| Primary mechanism | Central melanocortin signalling | PDE5 inhibition | PDE5 inhibition |
| Main research interest | Sexual desire and CNS pathways | Erectile function | Erectile function |
| Direct vascular mechanism | Not primary | Yes | Yes |
The distinction is important: PT-141 investigates a different biological pathway from conventional PDE5 inhibitors.
Safety, Side Effects & Toxicological Considerations
Although Bremelanotide has undergone clinical investigation, its pharmacological activity is associated with several recognised adverse effects.
Commonly reported adverse reactions include:
- Nausea.
- Facial flushing.
- Headache.
- Vomiting.
- Injection-site reactions.
- Dizziness.
- Fatigue.
- Nasal congestion.
Important cardiovascular considerations
Bremelanotide can cause a temporary increase in blood pressure accompanied by a reduction in heart rate.
The approved pharmaceutical product is contraindicated in individuals with uncontrolled hypertension or known cardiovascular disease.
Other important considerations:
- Focal hyperpigmentation can occur, particularly with repeated exposure.
- Gastric emptying may be delayed.
- The absorption of certain orally administered medications may be affected.
- Particular attention is required when evaluating interactions with medications such as naltrexone.
Because research-grade peptide preparations are not necessarily equivalent to approved pharmaceutical products, their purity, sterility, concentration and stability must be independently established.
Dosage Information & Clinical Reference
The FDA-approved Bremelanotide formulation, marketed as Vyleesi in the United States, has a specific prescription indication for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Its approved pharmaceutical presentation contains 1.75 mg of Bremelanotide in a prefilled subcutaneous autoinjector.
This is a prescription-specific clinical formulation, not a general dosing recommendation for research peptides.
Important: There is no validated human dosing protocol for unapproved research-grade PT-141 powders or preparations. The approved product’s instructions should not be used to calculate doses from research vials.
Storage & Stability
Peptide stability depends on formulation, manufacturing quality and environmental conditions.
Important quality-control considerations include:
- Protection from excessive heat.
- Protection from moisture and direct light.
- Verification of peptide identity and purity.
- Assessment of degradation products.
- Maintenance of appropriate storage conditions specified by the manufacturer.
Lyophilised peptide and reconstituted pharmaceutical solutions can have substantially different stability profiles. Storage periods should therefore be based on validated product-specific stability information rather than assumed shelf-life estimates.
Regulatory Status
Bremelanotide has received FDA approval in the United States under the brand name Vyleesi for a specific indication involving premenopausal women with acquired, generalized HSDD.
However, this approval does not extend automatically to:
- Research-grade PT-141 powders.
- Unapproved injectable preparations.
- Other formulations or administration routes.
- General treatment of erectile dysfunction in men.
Regulatory classification and availability vary between countries.
Summary
PT-141 (Bremelanotide) is a synthetic cyclic melanocortin peptide with a distinctive pharmacological profile involving central nervous system signalling.
Unlike conventional erectile dysfunction medications, which primarily target PDE5 and vascular smooth muscle, Bremelanotide interacts with melanocortin receptors involved in neuroendocrine and behavioural regulation.
Its clinical development and research applications make it an important compound in the study of sexual desire, melanocortin pharmacology and central sexual-response pathways.
Research-grade preparations should not be considered interchangeable with approved pharmaceutical Bremelanotide.





Reviews
There are no reviews yet.